Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Efficacy And Safety Of Ipilimumab Monotherapy In Patients With Pretreated Advanced Melanoma: A Multicenter Single-arm Phase II Study.

S. O’Day, M. Maio, V. Chiarion-Sileni, T. Gajewski, H. Pehamberger, I. Bondarenko, P. Queirolo, L. Lundgren, S. Mikhailov, L. Roman, C. Verschraegen, R. Humphrey, R. Ibrahim, V. de Pril, A. Hoos, J. Wolchok
Published 2010 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
BACKGROUND This phase II study evaluated the safety and activity of ipilimumab, a fully human mAb that blocks cytotoxic T-lymphocyte antigen-4, in patients with advanced melanoma. PATIENTS AND METHODS Patients with previously treated, unresectable stage III/stage IV melanoma received 10 mg/kg ipilimumab every 3 weeks for four cycles (induction) followed by maintenance therapy every 3 months. The primary end point was best overall response rate (BORR) using modified World Health Organization (WHO) criteria. We also carried out an exploratory analysis of proposed immune-related response criteria (irRC). RESULTS BORR was 5.8% with a disease control rate (DCR) of 27% (N = 155). One- and 2-year survival rates (95% confidence interval) were 47.2% (39.5% to 55.1%) and 32.8% (25.4% to 40.5%), respectively, with a median overall survival of 10.2 months (7.6-16.3). Of 43 patients with disease progression by modified WHO criteria, 12 had disease control by irRC (8% of all treated patients), resulting in a total DCR of 35%. Adverse events (AEs) were largely immune related, occurring mainly in the skin and gastrointestinal tract, with 19% grade 3 and 3.2% grade 4. Immune-related AEs were manageable and generally reversible with corticosteroids. CONCLUSION Ipilimumab demonstrated clinical activity with encouraging long-term survival in a previously treated advanced melanoma population.
This paper references
10.1200/JCO.2007.12.7837
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.
E. Korn (2008)
10.1245/ASO.2005.03.536
Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study
A. Maker (2005)
10.1038/nrc2051
Immunostimulatory monoclonal antibodies for cancer therapy
I. Melero (2007)
10.1002/ijc.21264
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma
W. Kruit (2005)
10.1158/1078-0432.CCR-07-0187
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
Stephanie G Downey (2007)
10.1200/jco.2009.27.15_suppl.9008
Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab.
O. Hamid (2009)
Anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events
JS Weber (2007)
10.1200/JCO.2008.26.15_SUPPL.9022
Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX- 010) with or without dacarbazine
Evan M. Hersh (2008)
10.1002/cncr.24951
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
G. Ku (2010)
10.1158/1078-0432.CCR-09-1624
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
J. Wolchok (2009)
10.1073/PNAS.94.15.8099
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer.
E. Kwon (1997)
10.1126/science.271.5256.1734
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
A companion study for patients enrolled in prior/parent ipilimumab studies http://clinicaltrials.gov/show
Clinicaltrials (2009)
10.1002/cncr.23086
Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)
S. O’Day (2007)
10.1586/era.09.25
Current systemic therapy for metastatic melanoma
S. Agarwala (2009)
10.1200/JCO.2007.15.7636
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
A. Hauschild (2009)
10.1200/JCO.2008.17.8954
Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
L. Fong (2008)
10.1016/J.COI.2006.01.011
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.
K. Peggs (2006)
10.2307/2530286
A Confidence Interval for the Median Survival Time
R. Brookmeyer (1982)
10.1093/BIOMET/26.4.404
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
C. J. Clopper (1934)
10.1158/1078-0432.CCR-09-1024
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
J. Weber (2009)
10.1634/THEONCOLOGIST.12-7-864
Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
J. Weber (2007)
10.1073/pnas.0830997100
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
F. S. Hodi (2003)
10.1200/JCO.2008.16.1927
Phase I/II study of ipilimumab for patients with metastatic melanoma.
J. Weber (2008)
10.1016/S1470-2045(09)70334-1
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
J. Wolchok (2010)
10.1200/JCO.2008.26.15_SUPPL.3022
Potential immune biomarkers of gastrointestinal toxicities and efficacy in patients with advanced melanoma treated with ipilimumab with or without prophylactic budesonide
D. Berman (2008)
10.1097/01.cji.0000208259.73167.58
Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma
A. Maker (2006)
Treatment guidelines for the management of immune-related adverse events in patients treated with ipilimumab, an antiCTLA4 therapy
K Chin (2008)
10.1200/JCO.2008.26.15_SUPPL.LBA9011
Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma
A. Ribas (2008)
10.1007/s00262-008-0653-8
Ipilimumab: controversies in its development, utility and autoimmune adverse events
J. Weber (2008)
10.1200/JCO.2005.06.205
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
P. Attia (2005)
10.1200/JCO.2005.08.375
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
N. van Baren (2005)
10.1080/07357900802027073
Prognostic Factors That Determine the Long-Term Survival of Patients with Unresectable Metastatic Melanoma
Agop Y. Bedikian (2008)



This paper is referenced by
10.1111/j.1610-0387.2010.07568_suppl.x
Behandlung und Nebenwirkungsmanagement des metastasierten Melanoms mit CTLA‐4‐Antikörpern
K. Kähler (2011)
10.1080/2162402X.2017.1344805
Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis
D. Wang (2017)
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.
J. Weber (2013)
10.1177/030089161209800202
Adjuvant Therapy for Resected Stage III Melanoma Patients: High-Dose Interferon-Alpha versus Ipilimumab Combined with Kinases Inhibitors
E. Minutilli (2012)
10.1007/978-3-319-58256-6
Current and Emerging Therapies in Pancreatic Cancer
T. Bekaii-Saab (2018)
10.1158/1078-0432.CCR-11-1203
A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma
T. Eigentler (2011)
10.1158/1078-0432.CCR-13-0895
Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
M. Nishino (2013)
10.1038/nrd3974
Challenges and approaches for the development of safer immunomodulatory biologics
Jean G. Sathish (2013)
10.1080/14740338.2016.1248402
The safety of anti PD-1 therapeutics for the treatment of melanoma
E. Ramelyte (2017)
10.1210/jc.2014-2306
Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma.
A. Faje (2014)
10.1093/annonc/mdt161
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.
J. Wolchok (2013)
10.2147/CCID.S24246
Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma
G. Tosti (2013)
10.1016/S0151-9638(13)70144-3
Quoi de neuf en cancérologie cutanée
Gaëlle Quéreux (2013)
Stereotactic radiosurgery and immunotherapy for metastatic spinal melanoma
Weill Cornell (2015)
10.1159/000490025
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
Yinghao Zhao (2018)
10.3109/1547691X.2012.678021
Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1
E. Simeone (2012)
10.1126/scitranslmed.3008002
Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
Shintaro Iwama (2014)
10.1007/s00345-015-1709-y
Immune checkpoint inhibitors: a new frontier in bladder cancer
M. Kates (2015)
10.3390/ijms20102560
Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies
S. Ferrari (2019)
10.2217/nnm-2017-0296
Targeted microbubbles with ultrasound irradiation and PD-1 inhibitor to increase antitumor activity in B-cell lymphoma.
Shiya Zheng (2018)
10.1007/978-1-62703-727-3_1
Novel insights/translational implication from the emerging biology of melanoma.
A. Ribas (2014)
10.1007/s40263-016-0392-x
Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications
M. Liu (2016)
10.1186/1479-5876-9-196
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
P. Ascierto (2011)
10.1634/theoncologist.2012-0391
Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.
J. Luke (2013)
10.1155/2013/423829
Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
B. Chmielowski (2013)
10.1097/CMR.0b013e32834d3d88
Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial
J. Weber (2011)
10.1155/2012/182157
Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
G. Piérard (2012)
10.1111/his.14000
Immune‐related adverse reactions in the hepatobiliary system: second‐generation check‐point inhibitors highlight diverse histological changes
Y. Zen (2019)
10.1016/j.ejca.2016.12.001
Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature.
S. Cuzzubbo (2017)
10.1016/j.hoc.2018.12.005
Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy.
Emanuelle M. Rizk (2019)
10.1097/CCO.0000000000000293
Endocrinological side-effects of immune checkpoint inhibitors
F. Torino (2016)
10.1002/cam4.732
Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta‐analysis of anti‐CTLA‐4 and anti‐PD‐1 agents trials
Seongseok Yun (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar